Showing results (651-660 of 667) with videos related to

Sort By:
Pageof 67
Cancer Communications (London, England)|October 2, 2025
Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trialsJian Li, Ting Deng, Yanhong Gu, et al.
Nature Communications|September 28, 2023
Defining the condensate landscape of fusion oncoproteinsSwarnendu Tripathi, Hazheen K Shirnekhi, Scott D Gorman, et al.
The Journal of Clinical Investigation|March 2, 2026
Macrophage-rich niches regulate T cell dynamics at the liver invasive margin during gallbladder cancer progressionMaolan Li, Zhaonan Liu, Shenbing Shan, et al.
Science Advances|March 27, 2026
One-component ionizable amphiphilic Janus dendrimers as a delivery platform for efficient mRNA vaccine developmentNathan A Ona, Dapeng Zhang, Lisa C Lindesmith, et al.
Cancer Cell|April 24, 2026
JYP0322, a highly selective and brain-penetrant ROS1 inhibitor, overcomes ROS1<sup>G2032R</sup> resistance mutation in NSCLC: The first-in-human phase 1 trialYuxiang Ma, Jinhui Xue, Fangfang Gao, et al.
Journal of Hepatology|June 25, 2021
Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancerYijian Zhang, Chunman Zuo, Liguo Liu, et al.
The Lancet. Gastroenterology & Hepatology|December 4, 2025
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRAS<sup>G12C</sup> mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trialsJian Li, Zhenghang Wang, Jing Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2025
Amivantamab Plus Lazertinib in Atypical <i>EGFR</i>-Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2Pascale Tomasini, Yongsheng Wang, Yongsheng Li, et al.
Physical Review Letters|May 15, 2018
First Octahedral Spherical Hohlraum Energetics Experiment at the SGIII Laser FacilityWen Yi Huo, Zhichao Li, Yao-Hua Chen, et al.
Signal Transduction and Targeted Therapy|February 27, 2025
Safety, pharmacokinetics and efficacy of HA121-28 in patients with advanced solid tumors and RET fusion-positive non-small-cell lung cancer: a multicenter, open-label, single-arm phase 1/2 trialDan-Yun Ruan, Wen-Wen Huang, Yongsheng Li, et al.
Pageof 67